2022 Nasopharyngeal Carcinoma Gordon Research Conference

摘要 鼻咽癌(NPC)和口咽癌(OPC)是头颈部常见的两种上皮性病变 与病毒感染有关的癌症。虽然这两种癌症都起源于咽部，但它们的解剖结构 而且地理分布和病毒联系也很明显。鼻咽癌，与Epstein-Barr病毒有关 (EBV)，局限于鼻咽，在东南亚、北非、格陵兰、 还有阿拉斯加。在美国，这在高加索人中很罕见，但在亚裔中很常见， 拉美裔和非裔美国人。相比之下，OPC通常与人乳头瘤病毒有关 人乳头瘤病毒(HPV)，局限于口咽部，在西半球白人男性中发病率最高。 这两种独特癌症的病因包括三个重要的辅助因素：宿主遗传、病毒感染和 环境影响。这些因素是如何促进这些癌症的发展的 是世界各地众多实验室的焦点。因为它们的位置和早期淋巴扩散的倾向， NPC和OPC都是晚期诊断，需要积极的治疗。了解病毒式传播 感染导致正常细胞癌变，这些细胞如何逃脱免疫监视，以及 介导肿瘤进展和治疗耐药的关键途径有望带来更好的治疗工具 早期诊断和有效的治疗最终将改善这些癌症的结果。 病毒感染、宿主遗传学、宿主免疫功能和流行病学因素的汇聚，使 这两种癌症建立了强大的模型来描述宿主-病毒-环境的相互作用，从而产生了新的 对肿瘤发病机制的洞察。重要的是，将两种不同的病毒驱动的癌症纳入同一 小型、亲密的会议将促进合作，推进两种癌症的研究步伐。我们 假设2022年会议，以鼻咽癌尖端基础、翻译和临床研究为特色 和OPC，并为基础科学家、临床医生和行业之间的思想交流提供了一个独特的论坛，Will 帮助扩大将新知识转化为病人护理的能力。我们将通过三个具体的例子来说明这一假设 目的：(1)通过以下途径提高对NPC和OPC的研究和临床护理的整体认识 制定一个令人振奋的科学计划，并为两国之间的关键互动提供一个刺激论坛 基础和临床科学家；(2)促进职业发展，提高新的知名度 调查人员和受训人员通过小型讲座和高参与度的海报会议，并提供部分 会议支持；及(3)加强全国人大GRC与会者的多样性，重点是妇女和城市管理 与会者和来自发展中国家(鼻咽癌流行的地方)的人通过我们的努力提供部分 会议支持并促进这些小组的口头陈述。我们认为，科学环境 在2022年NPC/OPC GRC会议上创建的GRC将有助于推进病毒驱动的头部和 以改善对这些患者的整体护理和治疗。

Abstract Nasopharyngeal carcinoma (NPC) and oropharyngeal carcinoma (OPC) are 2 common head and neck epithelial cancers that are associated with viral infection. Although both cancers arise from the pharynx, their anatomic and geographic distribution as well as viral linkage are distinct. NPC, which is linked to the Epstein-Barr Virus (EBV), is localized to the nasopharynx and has the highest incidence in Southeast Asia, North Africa, Greenland, and Alaska. In the United States (US), it is rare among Caucasians but is common among ethnic Asians, Hispanics and African Americans. In contrast OPC, which is commonly linked to the Human Papillomavirus (HPV), is localized to the oropharynx and has the highest incidence in white males in the Western hemisphere. The etiologies of these two unique cancers include three significant co-factors: host genetics, viral infection and environmental influences. How these factors contribute to the development of these cancers is the research focus of numerous laboratories worldwide. Because of their locations and proclivity for early lymphatic spread, both NPC and OPC are diagnosed at advanced stage, requiring aggressive therapy. Understanding how viral infection drives normal cells to become cancerous, how these cells escape from immune surveillance, and the critical pathways mediating tumor progression and treatment resistance are expected to lead to better tools for early diagnosis and effective therapies that would ultimately improve outcome of these cancers. The convergence of a virus infection, host genetics, host immune function, and epidemiological factors, makes these two cancers powerful models to delineate the host-virus-environment interactions, thereby yielding new insights into tumor pathogenesis. Importantly, the inclusion of two different virally driven cancers at the same small, intimate meeting will catalyze collaborations and advance the pace of research in both cancers. We hypothesize that the 2022 meeting, which features cutting edge basic, translational, and clinical research in NPC and OPC and provides a unique forum for idea exchange among basic scientists, clinicians, and industry, will help to expand the translation of new knowledge to patient care. We will address this hypothesis via three specific aims: (1) To advance the overall knowledge in research and clinical care of NPC and OPC through the development of an exciting scientific program and provision of a stimulating forum for critical interactions between the basic and clinical scientists; (2) To foster the career development and enhance the visibility of new investigators and trainees through the mini talks and highly engaged poster sessions and provision of partial meeting support; and (3) To enhance the diversity of NPC GRC participants with a focus on woman and URM attendees and those from developing countries (where NPC is endemic) through our effort to provide partial meeting support and promote oral presentations from these groups. We believe that the scientific environment created at the 2022 NPC/OPC GRC meeting will help to advance the field of research in virally-driven head and neck cancers in order to improve the overall care and cure of these patients.